Table 5.
Sub-Group Analyses for Repeat Hospitalizations
| Repeat Hospitalizations | Greater LVMi Regression % (no.) |
Lesser LVMi Regression % (no.) |
Hazard Ratio (95% CI) |
p-value |
|---|---|---|---|---|
| Overall population | n=344 | n=346 | ||
| Repeat hospitalizations | 9.5% (30) | 18.5% (59) | 0.50 [0.32, 0.78] | 0.002 |
| Trial Group | p for interaction = 0.16 | |||
| TAVR Cohort A RCT | n=63 | n=74 | ||
| 13.8% (8) | 16.3% (11) | 0.90 [0.36, 2.24] | 0.82 | |
| TAVR Cohort A NRCA | n=281 | n=272 | ||
| 8.6% (22) | 19.0% (48) | 0.43 [0.26, 0.71] | 0.0007 | |
| Access Route | p for interaction = 0.54 | |||
| Transfemoral | n=179 | n=197 | ||
| 8.9% (15) | 15.4% (28) | 0.57 [0.30, 1.06] | 0.07 | |
| Transapical | n=165 | n=149 | ||
| 10.1% (15) | 22.6% (31) | 0.43 [0.23, 0.80] | 0.006 | |
| Sex | p for interaction = 0.46 | |||
| Male | n=151 | n=152 | ||
| 13.5% (19) | 23.3% (32) | 0.57 [0.32, 1.01] | 0.05 | |
| Female | n=193 | n=194 | ||
| 6.2% (11) | 15.0% (27) | 0.41 [0.20, 0.82] | 0.009 | |
| Relative wall thickness | p for interaction = 0.12 | |||
| RWT ≥ median | n=186 | n=159 | ||
| 11.0% (19) | 15.5% (23) | 0.71 [0.39, 1.30] | 0.26 | |
| RWT < median | n=158 | n=187 | ||
| 7.5% (11) | 21.0% (36) | 0.35 [0.18,0.68] | 0.001 | |
| LV end-diastolic dimension | p for interaction = 0.40 | |||
| LVEDD ≥ median | n=166 | n=177 | ||
| 14.4% (22) | 24.5% (40) | 0.58 [0.35, 0.98] | 0.04 | |
| LVEDD < median | n=178 | n=169 | ||
| 4.9% (8) | 12.2% (19) | 0.38 [0.17, 0.88] | 0.02 | |
| Ejection fraction | p for interaction = 0.14 | |||
| EF ≥50% | n=216 | n=195 | ||
| 9.6% (19) | 13.6% (24) | 0.71 [0.39, 1.30] | 0.27 | |
| EF <50% | n=127 | n=151 | ||
| 9.3% (11) | 24.8% (35) | 0.36 [0.18, 0.71] | 0.002 | |
| Midwall fractional shortening | p for interaction = 0.48 | |||
| MFS ≥ median | n=177 | n=149 | ||
| 8.5% (14) | 19.0% (26) | 0.45 [0.23,0.86] | 0.01 | |
| MFS < median | n=141 | n=185 | ||
| 10.8% (14) | 17.0% (29) | 0.62 [0.33, 1.18] | 0.14 | |
| Stroke volume index | p for interaction = 0.23 | |||
| SVi ≥35 raL/m2 | n=194 | n=175 | ||
| 7.3% (13) | 18.0% (29) | 0.39 [0.20, 0.75] | 0.003 | |
| SVi <35 mL/m2 | n=144 | n=165 | ||
| 13.0% (17) | 18.9% (29) | 0.68 [0.37, 1.24] | 0.2 | |
| Mean gradient | p for interaction = 0.28 | |||
| MG ≥40 mmHg | n=216 | n=191 | ||
| 6.4% (13) | 15.3% (27) | 0.40 [0.21, 0.78] | 0.005 | |
| MG <40 mmHg | n=122 | n=150 | ||
| 14.6% (16) | 22.5% (31) | 0.66 [0.36, 1.22] | 0.18 | |
| 30 day paravalvular AR | p for interaction = 0.18 | |||
| Mod/severe paravalvular AR | n=38 | n=44 | ||
| 22.4% (8) | 24.6% (10) | 0.92 [0.36, 2.32] | 0.85 | |
| No/trace/mild paravalvular AR | n=306 | n=299 | ||
| 7.8% (22) | 17.4% (48) | 0.44 [0.27, 0.73] | 0.001 | |
Cox proportional hazards models were used to evaluate the hazard ratios for patients in each subgroup for the outcome of repeat hospitalizations and the interaction between each sub-group and LVMi regression (greater vs. lesser regression from baseline to 30 days post-TAVR based on sex-specific median % change in LVMI) for repeat hospitalizations.